Phase 3 N=312 Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
Toothache
Primary: Summed Pain Intensity Difference (SPID) — 25.9; -3.1; 8.8; -1.0 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,000 Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy
Colonoscopy · Endoscopy, Digestive System · Conscious Sedation
Primary: Area Under the Curve for Oxygen Desaturation (AUCDesat) — 23.6; 88.0 seconds*percent of oxygen desaturation — p=0.028
Phase 3 N=105 Clinical Study to Examine Brushing on Dental Implants
Gingival Diseases
Primary: Mombelli Plaque Index (mPI) for Natural Teeth — 1.96; 1.82 units on a scale — p=0.05
Phase 3 N=385 Efficacy and Safety Study for an Oral Contraceptive Containing Folate
Neural Tube Defects · Contraception · Oral Contraceptives (OC)
Primary: Red Blood Cell (RBC) Folate Level at 24 Weeks — 1406.91; 1022.21 nmol/L — p=<0.0001
Phase 3 N=100 Phase IIIB Subcutaneous Abatacept Monotherapy Study
Rheumatoid Arthritis (RA)
Primary: Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study — 0; 0 participants
Phase 3 N=146 Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
Diabetes · Diabetes Mellitus, Type 1
Primary: Insulin Detemir-insulin Aspart Cross-reacting Antibodies — 31.11; 43.99; 35.96; 31.22 Percent bound of total
Phase 3 N=238 Immunology and Safety of Menactra® in Children in Saudi Arabia
Meningitis · Meningococcemia
Primary: Geometric Mean Titers (GMTs) as Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination. — 168.9; 196.4; 6991.7…
Phase 3 N=1,700 Study of Safety and Efficacy of an Oral Contraceptive
Contraception
Primary: Pearl Index, 18-35 Years, MITT Population — 1.903 Pearl Index
Phase 3 N=431 Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation…
Phase 3 N=339 Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
Erectile Dysfunction
Primary: Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF) — 10.3; 1.7; 6.7; 1.1 scores…
Phase 3 N=36 A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Type 2 Diabetes
Primary: Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12 — 15.9; -2.2 Percent Change…
Phase 3 N=362 Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction
Erectile Dysfunction
Primary: Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or LOCF — 9.6; 2.1; 7.7; 0.9 scores on a scale — p=< 0.0001
Phase 3 N=250 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
Opiate Dependence
Primary: Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A) — 90.0; 35.0 Percentage of opioid-free weeks — p=0.0002
Phase 3 N=688 Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12) — -30.01; -20.29 mm Hg
Phase 3 N=540 Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
Chronic Hepatitis C · Liver Fibrosis
Primary: Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3). — 44; 29…